Corporate Banner
Satellite Banner
Technology Networks Header
Monday, September 22, 2014
 
Register | Sign in
Home Page > Application Notes
  Application Notes
Scientific News
New Approach To Arthritis Treatment
A new approach to arthritis treatment, which avoids unforeseen side-effects by delivering drugs exclusively to affected inflamed joints, has been developed by researchers at Queen Mary University of London.
Promise for Treatment of Pancreatic Cancer
Ultrasound microbubbles can improve tumor absorption of cancer drugs.
How Epigenetic Memory is Passed Across Generations
Researchers traced markers of gene repression through cell division and showed that both sperm and eggs transmit a memory of gene repression to embryos.
Stem Cells Use “First Aid Kits” to Repair Damage
Neural stem cells - master cells that can develop into any type of nerve cell - are able to generate mini “first aid kits” and transfer them to immune cells, according to a study published.
Reliable and Highly Efficient Method for Making Stem Cells
New finding could accelerate research to regenerate damaged tissue.
A New Molecule Allows for an Increase in Stem Cell Transplants
A clinical study using UM171 and a new type of bioreactor developed for stem culture will be initiated in December 2014.
Spontaneous Mutations in Key Brain Gene are a Cause of Autism
In addition, there is a direct link between TBR1 and FOXP2, a well-known language-related protein, researchers report.
Merck Animal Health to Market Neogen's Dairy Genomic Program
Agreement to market Neogen's Igenity® Dairy Heifer Program.
Asuragen’s Xpansion Interpreter® Test Study of 1,040 Transmissions of Fragile X Alleles
Study reveals personalized risks for expansion from parent to child.
A Big Step Towards More Efficient Photosynthesis
For the first time flowering plants have been successfully engineered to fix carbon like the blue-green algae do - this can potentially increase photosynthesis and yields in crop plants.
Scroll Up
Scroll Down

Efficient Delivery of Thermo Scientific Dharmacon SMARTpool siRNA Reagents in Difficult-to-Transfect Cell Lines Using Nucleofector® 96-well Shuttle® System
Bookmark and Share
Lonza


For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



Lonza and BioWa Sign Licensing Agreement with MedImmune
MedImmune has licensed Potelligent® CHOK1SV Cell Line Technology to both Companies.
Monday, December 16, 2013
Lonza and Hyglos Reach Agreement for Endotoxin Detection Patents
Agreement allows Hyglos to use recombinant factor C technology to produce its own endotoxin products.
Friday, March 15, 2013
Lonza to Expand ADC Manufacturing Capacity
Capacity expansion is expected to be complete in the second quarter of 2014.
Thursday, January 10, 2013
Lonza and Agennix Sign Development and Manufacturing Deal for Production of Talactoferrin
Lonza will manufacture talactoferrin at its microbial facility in Kourim, Czech Republic.
Thursday, April 19, 2012
Lonza Appoints Richard Ridinger as New CEO
Board of Directors elects Mr. Ridinger at a meeting on 2 April 2012.
Thursday, April 05, 2012
Lonza Expands Singapore Bioservices
The expansion will support cell line construction, upstream and downstream process development, and a broad range of analytical services.
Monday, June 13, 2011
Lonza Selects IDBS to Optimize Bioprocess Execution & Knowledge Management
Lonza has chosen IDBS to provide an electronic data management and execution solution for mammalian cell culture process development. Lonza will deploy IDBS's Bioprocess Execution System to optimize the management of process development data and drive operational excellence.
Wednesday, January 05, 2011
Lonza Acquires Viral Vaccine and Vector Manufacturer Vivante GMP Solutions
Lonza expands its custom service platform to viral vaccines and gene therapy vectors.
Tuesday, August 31, 2010
Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement
Lonza provides process development services and manufacturing capacity for this product using Lonza's GS Gene Expression System™.
Wednesday, June 17, 2009
Lonza Initiates Large Scale Production Capacity and Technology Platform for Antibody Drug Conjugates
Lonza plans to start large scale production of emerging product class Antibody Drug Conjugates to be utilized primarily in the treatment of cancer.
Friday, May 18, 2007
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv